SEARCH

SEARCH BY CITATION

References

  • 1
    Kronborg O, Ugstad M, Fuglerud P, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46: 795800.
  • 2
    Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 2001; 37: 8596.
  • 3
    Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36: 2916.
  • 4
    Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 45060.
  • 5
    Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 3626.
  • 6
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 1522.
  • 7
    Sampson B, Fagerhol MK, Sunderkotter C, et al. Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism. Lancet 2002; 360: 174245.
  • 8
    Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 17680.
  • 9
    Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 504.
  • 10
    Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem 2004; 41(Pt 3): 2302.
  • 11
    Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92(5 Pt 1): 12824.
  • 12
    Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 7882.
  • 13
    Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 157883.
    Direct Link:
  • 14
    Cirillo LC, Camera L, Della NM, Castiglione F, Mazzacca G, Salvatore M. Accuracy of enteroclysis in Crohn's disease of the small bowel: a retrospective study. Eur Radiol 2000; 10: 18948.
  • 15
    Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 11323.
  • 16
    Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003; 124: 172837.
  • 17
    Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 140730.
  • 18
    Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 50613.
  • 19
    Ton H, Brandsnes, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000; 292: 4154.